GSK Delivers on Q3, But the Post-Earnings Setup Shifts the Story

GSK plc reported third-quarter results on Wednesday, beating expectations and raising full-year guidance, and the week's question now is how positioning has adjusted in the wake of a print that the market had already been positioned to welcome.

The pre-earnings bullishness documented in this note three days ago has given way to a more settled picture. The stock closed at 1923.5p, up nearly 3% on the week and around 4% over the past month. That post-results gain is modest but consistent with the Q3 delivery: underlying operating profit beat expectations by 8%, respiratory and vaccine divisions led, and management lifted full-year guidance on oncology and specialty care momentum. Close peers moved in a similar direction. AZN added 1.6% on the week, Sanofi gained 2.1%, and JNJ led the peer group at 3.6%. GSK outpaced most of them. HLN, GSK's consumer health spin-off, was the outlier, essentially flat at 0.03% for the week.

The lending market carries no tension whatsoever. Availability is essentially unlimited, with the pool of shares available to borrow running at the maximum tracked level, meaning there is no scarcity of supply for anyone wanting to initiate or maintain a short position. Borrowing costs are 0.62%, up modestly from a week ago but still one of the lowest levels in the pharma sector. Short sellers have not returned in any meaningful way following the results: the ORTEX short score has ticked up slightly to 38.8 from 36.6 a week ago, but remains firmly in neutral territory and well below any level that would suggest a rebuilding bear position. For a £100 billion pharmaceutical name that just beat on profits, this is the expected outcome.

The Street picture is constructive but not freshly so. The most recent analyst data in the snapshot predates the results, meaning the consensus mean target of around 2173p (roughly 13% above current levels) does not yet reflect post-print revisions. The recent note from this series flagged an average 4% uplift in analyst price targets around the Q3 beat, which would add roughly 80p to that mean if applied uniformly. Valuation multiples give further colour: the trailing PE has drifted up to just over 10x over the past month as the share price has recovered, while EV/EBITDA remains around 7.5x. The dividend score ranks at the 90th percentile, earnings yield at the 93rd, both signals of a stock that looks inexpensive relative to its cash generation even after the recent rise. The short score rank of 57 and the utilization rank of 78 reflect the wide availability of borrow and the absence of meaningful short pressure.

Insider activity on October 12 adds a small but positive data point. CFO Julie Brown purchased 2,410 shares at 1735.5p, around 11% below where the stock trades now. The transaction is categorised as a "Buy" with a significance score of 3, modest but genuine. Several other executives filed transactions on the same date, though these are classified as "Other" rather than open-market purchases, likely reflecting dividend reinvestment or share plan activity rather than discretionary buying. Brown's purchase is the only clear signal of personal conviction in the group.

What to watch from here is whether analyst target revisions, which have not yet been captured in the consensus data, close the gap with a stock that has now partially re-rated, and whether management's raised guidance holds through Q4 as oncology and specialty care execution comes under closer scrutiny ahead of the February 2027 full-year results.